Isomab

IsomAb is developing isoform specific antibodies to treat patients with diseases that currently have limited or no treatment options. Its bioinformatics and knowledge-based platform approach has identified the therapeutic antibody ISM-001 as a development candidate for peripheral arterial disease (PAD). By progressing this through clinical trials, it has the potential to significantly improve the wellbeing of those affected by PAD which causes risk factors such as type 2 diabetes, obesity and high blood pressure.